亏损扩大、资产负债率高企 广济药业拟定增6亿元偿债和补流

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue A-shares to raise up to 600 million yuan for debt repayment and working capital, amid ongoing financial losses and high debt levels [2][3]. Group 1: Financial Performance - As of September 30, 2025, the company's debt-to-asset ratio stands at 62.67%, indicating a high level of financial leverage [2]. - The company has reported consecutive losses for three years, with projected net losses of 1.4 billion yuan in 2023 and 2.95 billion yuan in 2024, reflecting declines in revenue of 7.5% and 13.42% respectively [2]. - For 2025, the company anticipates further losses, with net profit expected to range between -5.18 billion yuan and -3.99 billion yuan due to ongoing market competition and low product prices [3]. Group 2: Capital Structure and Financing - The planned share issuance at a price of 6.32 yuan per share aims to optimize the capital structure and enhance risk resistance [2]. - The company has sought various bank credit facilities, including a 1.5 billion yuan credit from China Minsheng Bank and a 1.25 billion yuan credit from Huaxia Bank, to support operational needs [4]. - In January, the company announced a reduction of registered capital by 22 million yuan for its wholly-owned subsidiary to improve asset management efficiency [4].